Overview

Combination of PD-1 Monoclonal Antibody and HPV Vaccine in Patients With Cervical Cancer

Status:
Unknown status
Trial end date:
2021-03-31
Target enrollment:
Participant gender:
Summary
The investigators propose to evaluate the efficacy of the combination of Pd-1 Monoclonal Antibody and HPV Vaccine in the patients with cervical cancer who fails in or can not endure the standard treatment
Phase:
Phase 2
Details
Lead Sponsor:
Buhai Wang
Collaborator:
Innovent Biologics (Suzhou) Co. Ltd.
Treatments:
Antibodies
Antibodies, Monoclonal
Immunoglobulins
Vaccines